IDEAYA Biosciences (NASDAQ:IDYA) Given Overweight Rating at Stephens

Stephens restated their overweight rating on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a research note published on Friday,Benzinga reports. Stephens currently has a $50.00 price objective on the stock.

A number of other research firms also recently weighed in on IDYA. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Leerink Partners downgraded shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Wedbush reiterated an “outperform” rating and set a $52.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Finally, Oppenheimer reiterated an “outperform” rating and set a $53.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $53.58.

IDEAYA Biosciences Stock Performance

Shares of IDEAYA Biosciences stock opened at $21.00 on Friday. The company’s fifty day simple moving average is $24.49 and its 200-day simple moving average is $30.11. IDEAYA Biosciences has a 1 year low of $20.63 and a 1 year high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). Equities analysts forecast that IDEAYA Biosciences will post -2.45 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Aquatic Capital Management LLC raised its holdings in shares of IDEAYA Biosciences by 47.1% in the fourth quarter. Aquatic Capital Management LLC now owns 91,189 shares of the company’s stock valued at $2,344,000 after buying an additional 29,189 shares during the last quarter. Nebula Research & Development LLC raised its holdings in shares of IDEAYA Biosciences by 6.6% in the fourth quarter. Nebula Research & Development LLC now owns 75,417 shares of the company’s stock valued at $1,938,000 after buying an additional 4,654 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of IDEAYA Biosciences by 22.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,200,094 shares of the company’s stock valued at $30,842,000 after buying an additional 220,000 shares during the last quarter. Hsbc Holdings PLC raised its holdings in IDEAYA Biosciences by 66.6% during the 4th quarter. Hsbc Holdings PLC now owns 38,690 shares of the company’s stock worth $980,000 after purchasing an additional 15,465 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in IDEAYA Biosciences by 338.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,242 shares of the company’s stock worth $495,000 after purchasing an additional 14,852 shares during the last quarter. 98.29% of the stock is owned by institutional investors.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.